TheraTech Inc. Tuesday announced receipt of a National Institutes of Health grant that will fund initial studies of an innovative therapy for rheumatoid arthritis.

The grant, awarded under the NIH Small Business Innovation Research Program, will support a study using TheraTech's peptide-based cell-targeted system to deliver drugs directly to immune cells for the treatment of rheumatoid arthritis.